Molecular construction and optimization of anti-human IL-1α/β dual variable domain immunoglobulin (DVD-IgTM) molecules
暂无分享,去创建一个
T. Ghayur | Ling Santora | S. Bose | Chengbin Wu | Hua-Zong Ying | Renee Miller | L. Medina | Ling C Santora | Sahana Bose
[1] M. McDermott,et al. Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders. , 2009, Current opinion in molecular therapeutics.
[2] Iain B McInnes,et al. Evidence that cytokines play a role in rheumatoid arthritis. , 2008, The Journal of clinical investigation.
[3] W Wang,et al. Monoclonal Antibody Pharmacokinetics and Pharmacodynamics , 2008, Clinical pharmacology and therapeutics.
[4] E. Voronov,et al. Is interleukin‐1 a good or bad ‘guy’ in tumor immunobiology and immunotherapy? , 2008, Immunological reviews.
[5] J. Way,et al. The potential for cancer combination therapy with multi-targeted, single-protein pharmaceuticals , 2008, Expert opinion on drug discovery.
[6] Sahana Bose,et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin , 2007, Nature Biotechnology.
[7] P. Preshaw,et al. The expanding family of interleukin‐1 cytokines and their role in destructive inflammatory disorders , 2007, Clinical and experimental immunology.
[8] R. Kontermann,et al. Recombinant bispecific antibodies for cellular cancer immunotherapy. , 2007, Current opinion in molecular therapeutics.
[9] B. Robert,et al. In vivo Therapeutic Synergism of Anti–Epidermal Growth Factor Receptor and Anti-HER2 Monoclonal Antibodies against Pancreatic Carcinomas , 2007, Clinical Cancer Research.
[10] J. Dayer,et al. Is IL-1 a good therapeutic target in the treatment of arthritis? , 2006, Best practice & research. Clinical rheumatology.
[11] T. Lister,et al. Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Janice M Reichert,et al. Monoclonal antibody successes in the clinic , 2005, Nature Biotechnology.
[13] P. Hudson,et al. Engineered antibody fragments and the rise of single domains , 2005, Nature Biotechnology.
[14] J. Marvin,et al. Recombinant approaches to IgG-like bispecific antibodies , 2005, Acta Pharmacologica Sinica.
[15] D. Stuart,et al. Crystal structure of a soluble CD28-Fab complex , 2005, Nature Immunology.
[16] Sara Sandin,et al. Structure and flexibility of individual immunoglobulin G molecules in solution. , 2004, Structure.
[17] D. Bonn,et al. Two heads are better than one , 1999, Nature Methods.
[18] Stanley B. Cohen,et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. , 2002, Arthritis and rheumatism.
[19] K. Muegge,et al. Measurement of Soluble and Membrane‐Bound Interleukin 1 Using a Fibroblast Bioassay , 2000, Current protocols in immunology.
[20] G. Duff,et al. Arterial Inflammation in Mice Lacking the Interleukin 1 Receptor Antagonist Gene , 2000, The Journal of experimental medicine.
[21] L. Joosten,et al. IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. , 1999, Journal of immunology.
[22] L. Joosten,et al. Amelioration of established murine collagen‐induced arthritis with anti‐IL‐1 treatment , 1994, Clinical and experimental immunology.
[23] A. Lesk,et al. Canonical structures for the hypervariable regions of immunoglobulins. , 1987, Journal of molecular biology.